Search

Displaying results 1081 - 1090 of 2854 in total
  1. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022...

  2. Target

    Angiopoietin-1 receptor

    go.drugbank.com/bio_entities/BE0003379
    TargetHumans

    Tyrosine-protein kinase that acts as a cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskel...

    Synonyms: Tyrosine-protein kinase receptor TIE-2
  3. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

    Mixtures: Corzall PECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  4. Drug

    Choline

    go.drugbank.com/drugs/DB00122
    ApprovedInvestigationalNutraceutical

    A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.

    Mixtures: Sentravil PM-25, Sentrazolpidem PM-5
  5. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  6. Drug

    Lisinopril

    go.drugbank.com/drugs/DB00722
    ApprovedInvestigational

    Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiot...

    Mixtures: Lisnopril/hctz (type P), Lisnopril/hctz (type P)Products: Ratio-lisinopril P, Teva-lisinopril (type P)
  7. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  8. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a ne...

  9. Drug

    UniPR129

    go.drugbank.com/drugs/DB33097
    Experimental

    Categories: Bile Acids and Salts
  10. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury.